Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

NCT05030077 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Anlotinib
Urogenital Neoplasms
Cisplatin
Carboplatin
Gemcitabine
Antineoplastic Agents

Interventions

DRUG: Anlotinib
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Gemcitabine

Sponsor

Tianjin Medical University Second Hospital